|
1
|
Lee JK, Coutant C, Kim YC, Qi Y,
Theodorescu D, Symmans WF, Baggerly K, Rouzier R and Pusztai L:
Prospective comparison of clinical and genomic multivariate
predictors of response to neoadjuvant chemotherapy in breast
cancer. Clin Cancer Res. 16:711–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rouzier R, Pusztai L, Delaloge S,
Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR,
Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V,
Berry DA and Hortobagyi GN: Nomograms to predict pathologic
complete response and metastasis-free survival after preoperative
chemotherapy for breast cancer. J Clin Oncol. 23:8331–8339. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaufmann M, von Minckwitz G, Mamounas EP,
Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant
M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle
E, Semiglazov V, Symmans WF, Tutt A and Pusztai L: Recommendations
from an international consensus conference on the current status
and future of neoadjuvant systemic therapy in primary breast
cancer. Ann Surg Oncol. 19:1508–1516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
U.S. Department of Health and Human
Services, Food and Drug Administration, Center for Drug Evaluation
and Research (CDER): Guidance for Industry Pathological Complete
Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast
Cancer: Use as an Endpoint to Support Accelerated Approval.
Retrieved from. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdfApril
10–2014
|
|
5
|
Gianni L, Eiermann W, Semiglazov V,
Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M,
Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok
A, Baronio R, Feyereislova A, Barton C, Valagussa P and Baselga J:
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant
trastuzumab versus neoadjuvant chemotherapy alone, in patients with
HER2-positive locally advanced breast cancer (the NOAH trial): A
randomised controlled superiority trial with a parallel
HER2-negative cohort. Lancet. 375:377–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hutcheon AW, Heys SD and Sarkar TK:
Aberdeen Breast Group: Neoadjuvant docetaxel in locally advanced
breast cancer. Breast Cancer Res Treat. 79:(Suppl 1). S19–S24.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Untch M, Möbus V, Kuhn W, Muck BR,
Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A,
Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D,
Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F and Konecny
GE: Intensive dose-dense compared with conventionally scheduled
preoperative chemotherapy for high-risk primary breast cancer. J
Clin Oncol. 27:2938–2945. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuerer HM, Newman LA, Smith TL, Ames FC,
Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N,
Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and
Singletary SE: Clinical course of breast cancer patients with
complete pathologic primary tumor and axillary lymph node response
to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol.
17:460–469. 1999.PubMed/NCBI
|
|
9
|
Rouzier R, Extra J-M, Klijanienko J,
Falcou MC, Asselain B, Vincent-Salomon A, Vielh P and Bourstyn E:
Incidence and prognostic significance of complete axillary
downstaging after primary chemotherapy in breast cancer patients
with T1 to T3 tumors and cytologically proven axillary metastatic
lymph nodes. J Clin Oncol. 20:1304–1310. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esserman LJ, Berry DA, DeMichele A, Carey
L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C,
Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade
OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C,
Rabban J, Chen YY, Giri D, van't Veer L and Hylton N: Pathologic
complete response predicts recurrence-free survival more
effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB
150007/150012, ACRIN 6657. J Clin Oncol. 30:3242–3249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mazouni C, Peintinger F, Wan-Kau S, Andre
F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V,
Hortobagyi GN and Pusztai L: Residual ductal carcinoma in situ in
patients with complete eradication of invasive breast cancer after
neoadjuvant chemotherapy does not adversely affect patient outcome.
J Clin Oncol. 25:2650–2655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C,
Nekljudova V, Mehta K and Loibl S: Definition and impact of
pathologic complete response on prognosis after neoadjuvant
chemotherapy in various intrinsic breast cancer subtypes. J Clin
Oncol. 30:1796–1804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Montagna E, Bagnardi V, Rotmensz N, Viale
G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S,
Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG,
Bottiglieri L, Iorfida M, Goldhirsch A and Colleoni M: Pathological
complete response after preoperative systemic therapy and outcome:
Relevance of clinical and biologic baseline features. Breast Cancer
Res Treat. 124:689–699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
von Minckwitz G, Kaufmann M, Kuemmel S,
Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch
C, Gerber B, Du Bois A, Huober JB, Hanusch CA, Konecny GE, Fett W,
Stickeler E, Harbeck N, Mehta K, Loibl S and Untch M: and GBG and
AGO-B study groups: Correlation of various pathologic complete
response (pCR) definitions with long-term outcome and the
prognostic value of pCR in various breast cancer subtypes: Results
from the German neoadjuvant meta-analysis. J Clin Oncol.
29:10282011.
|
|
15
|
Caudle AS, Gonzalez-Angulo AM, Hunt KK,
Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi
GN and Meric-Bernstam F: Predictors of tumor progression during
neoadjuvant chemotherapy in breast cancer. J Clin Oncol.
28:1821–1828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boughey JC, Peintinger F, Meric-Bernstam
F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci
A, Buzdar AU, Pusztai L and Kuerer HM: Impact of preoperative
versus postoperative chemotherapy on the extent and number of
surgical procedures in patients treated in randomized clinical
trials for breast cancer. Ann Surg. 244:464–470. 2006.PubMed/NCBI
|
|
17
|
van Nes JG, Putter H, Julien JP,
Tubiana-Hulin M, van de Vijver M, Bogaerts J, de Vos M and van de
Velde CJ: Cooperating Investigators of the EORTC: Preoperative
chemotherapy is safe in early breast cancer, even after 10 years of
follow-up; clinical and translational results from the EORTC trial
10902. Breast Cancer Res Treat. 115:101–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang GC, Zhang YF, Xu FP, Qian XK, Guo
ZB, Ren CY and Yao M: Axillary lymph node status, adjusted for
pathologic complete response in breast and axilla after neoadjuvant
chemotherapy, predicts differential disease-free survival in breast
cancer. Curr Oncol. 20:e180–e192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ellis MJ, Tao Y, Luo J, A'Hern R, Evans
DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith
I, Eiermann W and Dowsett M: Outcome prediction for estrogen
receptor-positive breast cancer based on postneoadjuvant endocrine
therapy tumor characteristics. J Natl Cancer Inst. 100:1380–1388.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonzalez-Angulo AM, McGuire SE, Buchholz
TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P,
Ocana A, Cristofanilli M, Valero V, Buzdar AU and Hortobagyi GN:
Factors predictive of distant metastases in patients with breast
cancer who have a pathologic complete response after neoadjuvant
chemotherapy. J Clin Oncol. 23:7098–7104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tanioka M, Shimizu C, Yonemori K,
Yoshimura K, Tamura K, Kouno T, Ando M, Katsumata N, Tsuda H,
Kinoshita T and Fujiwara Y: Predictors of recurrence in breast
cancer patients with a pathologic complete response after
neoadjuvant chemotherapy. Br J Cancer. 103:297–302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
